Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares (Dividend Re-investment) |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.6781 |
| Volume | 930.908 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records an initial notification of a share acquisition by Mr. D S Redfern, Chief Strategy Officer, following the re-investment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific executive transaction.
Key Facts for Investor Verification
- Verify the identity of the PDMR: Mr. D S Redfern, Chief Strategy Officer.
- Confirm the transaction was an acquisition via dividend re-investment, not an open market purchase.
- Note the transaction price of £16.6781 per share on July 14, 2016.
- Recognize that this filing does not contain quarterly or annual financial results.